Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis (2024)

Abstract

Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.

Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.

Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).

Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.

Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

Original language	English
Article number	5463451
Number of pages	6
Journal	Multiple Sclerosis International
Volume	2020
DOIs	https://doi.org/10.1155/2020/5463451
Publication status	Published - 2020

Access to Document

10.1155/2020/5463451

5463451Final published version, 615 KB

Fingerprint

Dive into the research topics of 'Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this

APA
Author
BIBTEX
Harvard
Standard
RIS
Vancouver

Daniels, K., van der Nat, P. B., Frequin, S. T. F. M., van der Wees, P. J., Biesma, D. H., Hoogervorst, E. L. J. (2020). Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. Multiple Sclerosis International, 2020, Article 5463451. https://doi.org/10.1155/2020/5463451

Daniels, K ; van der Nat, P B ; Frequin, S T F M et al. / Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. In: Multiple Sclerosis International. 2020 ; Vol. 2020.

@article{f687cebb4ebb4069a719488f54706404,

title = "Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis",

abstract = "Background: Recently, ocrelizumab (Ocrevus{\textregistered}) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.",

author = "K Daniels and {van der Nat}, {P B} and Frequin, {S T F M} and {van der Wees}, {P J} and Biesma, {D H} and Hoogervorst, {E L J} and {van de Garde}, {E M W}",

note = "Copyright {\textcopyright} 2020 K. Daniels et al.",

year = "2020",

doi = "10.1155/2020/5463451",

language = "English",

volume = "2020",

journal = "Multiple Sclerosis International",

issn = "2090-2654",

publisher = "Hindawi Publishing Corporation",

}

Daniels, K, van der Nat, PB, Frequin, STFM, van der Wees, PJ, Biesma, DH, Hoogervorst, ELJ 2020, 'Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis', Multiple Sclerosis International, vol. 2020, 5463451. https://doi.org/10.1155/2020/5463451

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. / Daniels, K; van der Nat, P B; Frequin, S T F M et al.
In: Multiple Sclerosis International, Vol. 2020, 5463451, 2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

AU - Daniels, K

AU - van der Nat, P B

AU - Frequin, S T F M

AU - van der Wees, P J

AU - Biesma, D H

AU - Hoogervorst, E L J

AU - van de Garde, E M W

PY - 2020

Y1 - 2020

N2 - Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

AB - Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

U2 - 10.1155/2020/5463451

DO - 10.1155/2020/5463451

M3 - Article

C2 - 32607256

SN - 2090-2654

VL - 2020

JO - Multiple Sclerosis International

JF - Multiple Sclerosis International

M1 - 5463451

ER -

Daniels K, van der Nat PB, Frequin STFM, van der Wees PJ, Biesma DH, Hoogervorst ELJ et al. Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. Multiple Sclerosis International. 2020;2020:5463451. doi: 10.1155/2020/5463451

FAQs

Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis? ›

This real-world data study confirmed that ocrelizumab can stabilize disability progression in patients with PPMS. Interestingly, three out of 17 patients even showed clinically relevant improvement in disability status.

Find Out More ›

How effective is Ocrevus for primary progressive MS? ›

In a large clinical trial, fewer people with PPMS taking Ocrevus had an increase in disability; people taking Ocrevus were 24% less likely to have an increase in their disability than those taking placebo.

What is the success rate of ocrelizumab? ›

Over one year of observation, 83.6% of ocrelizumab recipients with RMS and 93.2% with PPMS experienced treatment success (defined as no relapse, progression or treatment discontinuation due to an adverse event); mean changes in EDSS from baseline to after one year of treatment were 0.0 and 0.1 in the respective groups.

How long after Ocrevus do you feel better? ›

Official answer. Ocrevus has some effect at reducing disability progression within about 12 weeks; however, it may take at least 6 months or possibly longer for the full effects to be seen.

View Details ›

Does PPMS ever get better? ›

With PPMS, neurologic functions get steadily worse in the beginning. There are no symptom flare-ups (also called relapses or attacks). And there is no recovery (remission). How fast the disease progresses may vary.

Know More ›

What is the new treatment for PPMS? ›

A new drug called ocrelizumab (Ocrevus) became available for primary progressive MS in 2018. It's an infusion you have every six months. To get it you must be early on in your primary progressive MS. Depending on your level of disability, 'early' means it's been between 10 and 15 years since your MS began.

Find Out More ›

Can Ocrevus make lesions go away? ›

OCREVUS WAS PROVEN TO REDUCE BRAIN LESIONS ON MRI.

T1 Gd+ lesions are thought to be a sign of active inflammation. The exact way OCREVUS works is not fully known.

What are the positive results from Ocrevus? ›

The results show that after 10 years of continuous Ocrevus treatment, 77% of patients with RMS had no disability progression and 92% of them continued to walk unassisted.

How many cases of PML with Ocrevus are there? ›

During this time, a total of 12 cases of PML were confirmed (Table 1). All 12 cases were confirmed in the setting of presence of JCV DNA in CSF along with a brain MRI consistent with the diagnosis of PML.

Discover More Details ›

Is Ocrevus highly effective? ›

90% of patients treated with OCREVUS showed no 12-week or 24-week confirmed disability progression in the controlled period.